VIR BIOTECHNOLOGY INC (VIR)
US92764N1028 - Common Stock
Overall VIR gets a fundamental rating of 4 out of 10. We evaluated VIR against 588 industry peers in the Biotechnology industry. VIR has a great financial health rating, but its profitability evaluates not so good. VIR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
VIR had negative earnings in the past year.
VIR had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VIR reported negative net income in multiple years.
In the past 5 years VIR reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of VIR (-32.05%) is better than 69.97% of its industry peers.
VIR has a better Return On Equity (-38.68%) than 76.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.05% | ||
| ROE | -38.68% | ||
| ROIC | N/A |
ROA(3y)4.47%
ROA(5y)-10.64%
ROE(3y)7.69%
ROE(5y)-11.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 96.87%, VIR belongs to the top of the industry, outperforming 97.78% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for VIR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.
VIR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VIR has more shares outstanding
There is no outstanding debt for VIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 1.61, we must say that VIR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.61, VIR is in the better half of the industry, outperforming 69.28% of the companies in the same industry.
VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.61 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
A Current Ratio of 9.05 indicates that VIR has no problem at all paying its short term obligations.
With a decent Current ratio value of 9.05, VIR is doing good in the industry, outperforming 77.99% of the companies in the same industry.
A Quick Ratio of 9.05 indicates that VIR has no problem at all paying its short term obligations.
The Quick ratio of VIR (9.05) is better than 78.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.05 | ||
| Quick Ratio | 9.05 |
3. Growth
3.1 Past
VIR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -220.47%.
Looking at the last year, VIR shows a very negative growth in Revenue. The Revenue has decreased by -94.67% in the last year.
Measured over the past years, VIR shows a very strong growth in Revenue. The Revenue has been growing by 51.78% on average per year.
EPS 1Y (TTM)-220.47%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-13.16%
Revenue 1Y (TTM)-94.67%
Revenue growth 3Y4.1%
Revenue growth 5Y51.78%
Revenue growth Q2Q-66.02%
3.2 Future
VIR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.42% yearly.
The Revenue is expected to grow by 56.27% on average over the next years. This is a very strong growth
EPS Next Y10.03%
EPS Next 2Y6.01%
EPS Next 3Y6.3%
EPS Next 5Y8.42%
Revenue Next Year-47.29%
Revenue Next 2Y-27.19%
Revenue Next 3Y-7.83%
Revenue Next 5Y56.27%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VIR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.01%
EPS Next 3Y6.3%
5. Dividend
5.1 Amount
No dividends for VIR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIR BIOTECHNOLOGY INC
NASDAQ:VIR (4/29/2024, 7:00:03 PM)
After market: 8.37 0 (0%)8.37
+0.14 (+1.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.13B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.05% | ||
| ROE | -38.68% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.87% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 9.05 | ||
| Quick Ratio | 9.05 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-220.47%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y10.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-94.67%
Revenue growth 3Y4.1%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y